Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Biomarkers of inflammation and epithelial barrier function in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Frederik Novak
  • Anna Christine Nilsson
  • Christian Nielsen
  • Dorte K Holm
  • Kamilla Østergaard
  • Anna Bystrup
  • Keld-Erik Byg
  • Isik S Johansen
  • Kristen Mittl
  • William Rowles
  • Kira Mcpolin
  • Collin Spencer
  • Sharon Sagan
  • Chloe Gerungan
  • Michael R Wilson
  • Scott S Zamvil
  • Riley Bove
  • Joseph J Sabatino
  • Tobias Sejbaek
View graph of relations

BACKGROUND: The immunogenicity of COVID-19 vaccine among patients receiving anti-CD20 monoclonal antibody (Ab) treatment has not been fully investigated. Detectable levels of SARS-CoV-2 immunoglobulin G (IgG) are believed to have a predictive value for immune protection against COVID-19 and is currently a surrogate indicator for vaccine efficacy.

OBJECTIVE: To determine IgG Abs in anti-CD20 treated patients with multiple sclerosis (MS).

METHOD: IgG Abs against SARS-CoV-2 spike receptor-binding domain were measured with the SARS-CoV-2 IgG II Quant assay (Abbott Laboratories) before and after vaccination (n = 60).

RESULTS: 36.7% of patients mounted a positive SARS-CoV-2 spike Ab response after the second dose of vaccine. Five patients (8.3%) developed Abs >264 BAU/mL, another 12 patients (20%) developed intermediate Abs between 54 BAU/mL and 264 BAU/mL and five patients (8.3%) had low levels <54 BAU/mL. Of all seropositive patients, 63.6% converted from seronegative to seropositive after the 2nd vaccine.

CONCLUSION: Our study demonstrates decreased humoral response after BNT162b2 mRNA SARS-CoV-2 vaccine in MS patients receiving B-cell depleting therapy. Clinicians should advise patients treated with anti-CD20 to avoid exposure to SARS-CoV-2. Future studies should investigate the implications of a third booster vaccine in patients with low or absent Abs after vaccination.

Original languageEnglish
Article number103251
JournalMultiple Sclerosis and Related Disorders
Volume56
Pages (from-to)103251
ISSN2211-0348
DOIs
Publication statusPublished - 2021

Bibliographical note

Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

ID: 68665037